Biomarker study for patients with metastatic colorectal cancer treated with anti-angiogenic agent using liquid biopsy - AAA-liquid

ippon Medical Scool0 个研究点目标入组 150 人开始时间: 2021年4月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Having UGT1A1*6 homo, UGT1A1*28 homo, and UGT1A1*6*28 double hetero Contraindicated for anti-VEGF inhibitor. Previous treatment with irinotecan Previous treatment with ramucirumab or aflibercept History of severe drug hypersensitivity Pregnant women or women who may become pregnant. Men whose partners wish to become pregnant. Patients with serious complications (interstitial pneumonia or pulmonary fibrosis, renal failure, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension) Patients with pleural effusion or ascites requiring treatment Patients with peritoneal dissemination that is considered likely to cause intestinal obstruction. Active multiple cancers. Significant ECG abnormalities or clinically problematic heart disease (heart failure, myocardial infarction, angina pectoris, etc.) Having brain metastases. Patients with active multiple cancers with a disease-free interval of less than 5 years (cured basal cell carcinoma of the skin and cervical cancer, or gastric cancer, esophageal cancer, and colorectal pM cancer confirmed to be cured by endoscopic mucosal resection may be enrolled. FDG-PET scan is not necessary, but bone metastasis should not be detected. The physician in charge considers the patient unsuitable for participation in this study.

发起方

ippon Medical Scool